INLEXZO

all catalysts(0)

nothing on the calendar yet

News(1)

• Tyra disappoints investors with bladder cancer data
  Remission rates observed in a Phase 2 trial fell short of Wall Street's expectations, though some analysts believe the company should see better results in late-stage testing.
  biopharma_dive · 6d ago